The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has awarded a $613,036 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to Fibrobiologics LLC, a for-profit biotechnology company. The funding supports the development of a novel peptide-based therapeutic agent, designated as M10, for the treatment of skin fibrosis associated with systemic sclerosis (scleroderma), an autoimmune rheumatic disease.
Specific objectives of the research project include: 1) determining the antifibrotic activity of M10 in primary skin fibroblasts isolated from scleroderma patients, and 2) evaluating the efficacious dosing of M10 in two different animal models of dermal fibrosis. The successful completion of these aims is expected to provide critical data to support further studies focused on gaining FDA clearance, scaling production, and conducting human clinical trials for this potential new therapeutic approach to address skin fibrosis in scleroderma patients.
Generated 3/4/25, 5:24 AM